Skip to Content
Merck

1.50575

LiChrospher® RP-select B (5 µm) HPLC Columns

L x I.D. 250 mm x 4.6 mm Hibar® RT HPLC Column

Synonym(s):

TM=["LiChrospher"] C8 HPLC column

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
41115709
NACRES:
SB.52
Particle size:
5 μm
Matrix active group:
C8 bonding phase
Pore size:
60 Å pore size
Matrix:
fully porous particle
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

LiChrospher® RP-select B (5µm) Hibar® RT 250-4.6, suitable for HPLC

material

stainless steel column

Quality Level

agency

suitable for USP L7

product line

LiChrospher®

feature

endcapped: no

extent of labeling

11.5% Carbon loading

parameter

400 bar pressure, 60 °C max. temp.

technique(s)

HPLC: suitable, mass spectrometry (MS): suitable (Low - Medium)

column L × I.D.

25 cm × 4.6 mm

surface area

350 m2/g

matrix

fully porous particle

matrix active group

C8 bonding phase

particle size

5 μm

pore size

60 Å pore size

operating pH range

2-7.5

separation technique

reversed phase, supercritical fluid (SFC)

storage temp.

no temp limit

General description

HPLC column
LiChrospher® RP-select B is a versatile traditionally produced spherical silica gel carriers with reversed phase properties and with the hydrophobicity of a C-8 phase. This carrier is very well suited for the separation of basic compounds, but with still good properties for the determination of neutral and acidic compounds. This sorbent is packed into a Hibar 100-4.6 HPLC column. For mounting of a LiChroCART 4-4 guard column, the guard column holder 1.51487 has to be used.

Application


  • Simultaneous quantification of delta-9-THC, THC-acid A, CBN and CBD in seized drugs using HPLC-DAD: This study utilizes high-performance liquid chromatography with diode-array detection (HPLC-DAD), employing a LiChrospher® RP-select B column to effectively separate and quantify cannabinoids in forensic samples, highlighting its application in legal and forensic settings (Ambach et al., 2014).

  • Structural characterization of stress degradation products of Darunavir: Employing LC-MS/MS alongside HPLC, this research underscores the utility of the LiChrospher® RP-select B column in the stability analysis of HIV medications, crucial for ensuring drug safety and efficacy (Rao et al., 2014).

  • RP-HPLC separation and characterization of unknown impurities of Darunavir: This study demonstrates the column′s role in identifying and quantifying impurities in HIV-protease inhibitors, contributing to the pharmaceutical industry′s quality control measures (Nageswara Rao et al., 2013).

  • Quantification of pralidoxime in urine by ion pair chromatography: The LiChrospher® RP-select B column is applied in a biomedical context to monitor therapeutic agents in clinical settings, supporting patient treatment regimes (John et al., 2012).

  • Liquid chromatography/electrospray tandem mass spectrometry method for determination of cefuroxime: This analytical method facilitates the study of pharmacokinetics in clinical pharmacology, using the LiChrospher® RP-select B column for precise drug monitoring in plasma (Partani et al., 2010).

Analysis Note

Pressure: ≤ 90 bar
Theoretical Plates (N/m) (Toluene): ≥ 50000
Symmetry (Toluene): 0.8 - 1.4
Capacity factor (Toluene): 1.0 - 2.0

Legal Information

Hibar is a registered trademark of Merck KGaA, Darmstadt, Germany
LiChrospher is a registered trademark of Merck KGaA, Darmstadt, Germany


Still not finding the right product?




Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library